Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro

Journal of Sexual Medicine

Volumn 8, Issue 3, 2011, Pages 696-704

  Aversa, Antonio ^a   Caprio, Massimiliano ^b   Antelmi, Antonella ^b   Armani, Andrea ^b   Brama, Marina ^a   Greco, Emanuela A ^a   Francomano, Davide ^a   Calanchini, Matilde ^c   Spera, Giovanni ^a   Luigi, Luigi Di ^d   Rosano, Giuseppe M C ^b   Lenzi, Andrea ^a   Migliaccio, Silvia ^a,d   Fabbri, Andrea ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

CYP19; Endothelial Health; Estradiol; Human Visceral Adipocytes; Nitric Oxide; PDE5 Inhibitors; Sildenafil; Tadalafil

Indexed keywords

8 BROMO CYCLIC GMP; AROMATASE; ESTRADIOL; LETROZOLE; MESSENGER RNA; MILRINONE; PHOSPHODIESTERASE V; SILDENAFIL; TADALAFIL; TESTOSTERONE;

ADIPOCYTE; ADULT; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; INTRAABDOMINAL FAT; LONG TERM EXPOSURE; MALE; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; WESTERN BLOTTING;

EID: 79951960347     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.02152.x     Document Type: Article

References (24)

1. Aversa A, Bruzziches R, Pili M, Spera G. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 2006;12:3467-84.
2. Manganiello V. Cyclic nucleotide phosphodiesterase 5 and sildenafil: Promises realized. Mol Pharmacol 2003;63:1209-11.
3. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, Munarriz R, Lee SW. Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7(1 Pt 2):524-40.
4. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type-5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253-63.
5. Moro C, Klimcakova E, Lafontan M, Berlan M, Galitzky J. Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis. Br J Pharmacol 2007;152:1102-10.
6. Taira M, Hockman SC, Calvo JC, Taira M, Belfrage P, Manganiello VC. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem 1993;268:18573-9.
7. Stief CG, Uckert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, Jonas U. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 2000;55:146-50.
8. Greco EA, Pili M, Bruzziches R, Corona G, Spera G, Aversa A. Testosterone: Estradiol ratio changes associated with long-term tadalafil administration: A pilot study. J Sex Med 2006;3:716-22.
9. Armani A, Mammi C, Marzolla V, Calanchini M, Antelmi A, Rosano GM, Fabbri A, Caprio M. Cellular models for understanding adipogenesis, adipose dysfunction, and obesity. J Cell Biochem 2010;110:564-72.
10. Nisoli E, Clementi E, Tonello C, Sciorati C, Briscini L, Carruba MO. Effects of nitric oxide on proliferation and differentiation of rat brown adipocytes in primary cultures. Br J Pharmacol 1998;125:888-94.
11. Fujinami A, Ohta K, Matsui H, Kitada N, Kitaura Y, Kawahara Y, Obayashi H, Kuno S, Nakamura N, Ohta M. Resistin concentrations in murine adipose tissue and serum measured by a new enzyme immunoassay. Obesity 2006;14:199-205.
12. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Grahm-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, Bulun SE. Aromatase Cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342-55.
13. Miller AP, Xing D, Feng W, Fintel M, Chen YF, Oparil S. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 2007;14:251-60.
14. Kim KH, Bender JR. Membrane-initiated actions of estrogen on the endothelium. Mol Cell Endocrinol 2009;308:3-8.
15. Florian M, Lu Y, Angle M, Magder S. Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation. Steroids 2004;69:637-45.
16. Guo X, Razandi M, Pedram A, Kassab G, Levin ER. Estrogen induces vascular wall dilation: Mediation through kinase signaling to nitric oxide and estrogen receptors α and β. J Biol Chem 2005;280:19704-10.
17. Traupe T, Stettler CD, Li H, Haas E, Bhattacharya I, Minotti R, Barton M. Distinct roles of estrogen receptors α and β mediating acute vasodilation of epicardial coronary arteries. Hypertension 2007;49:1364-70.
18. Jones ME, McInnes KJ, Boon WC, Simpson ER. Estrogen and adiposity-utilizing models of aromatase deficiency to explore the relationship. J Steroid Biochem Mol Biol 2007;106:3-7.
19. Misso ML, Murata Y, Boon WC, Jones ME, Britt KL, Simpson ER. Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse. Endocrinology 2003;144:1474-80.
20. McInnes KJ, Corbould A, Simpson ER, Jones ME. Regulation of adenosine 5', monophosphate-activated protein kinase and lipogenesis by androgens contributes to visceral obesity in an estrogen-deficient state. Endocrinology 2006;147:5907-13.
21. Seralini G, Moslemi S. Aromatase inhibitors: Past, present and future. Mol Cell Endocrinol 2001;178:117-31.
22. Zhang X, Ji J, Yan G, Wu J, Sun X, Shen J, Jiang H, Wang H. Sildenafil promotes adipogenesis through a PKG pathway. Biochem Biophys Res Commun 2010;396:1054-59.
23. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med 2009;6:1794-808.
24. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: Updates on optimal utilization for sexual concerns and rare toxicities in this class. J Sex Med 2009;6:2352-64.